Evidence map›Paper›PMID 22904637›Full record

ArticleCancer management and research2012

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution.

Albert Tuca, Ernest Guell, Emilio Martinez-Losada, Nuria Codorniu

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03260647 (Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction), which is not on this map. Cited by 113 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 7 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03260647 completednot on this mapstarted 2017, after this paper: background citation

Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction (MAMBO) Program for Women With Advanced Gynecological Cancers

TypeobservationalSponsorUniversity Health Network, TorontoRan2017 to 2024Enrolled96ConditionsGynecologic CancerArmsManagement algorithm for Malignant Bowel Obstruction
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 7 syntheses or guidelines pooled it, 269 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  6. Oral water soluble contrast for malignant bowel obstruction.The Cochrane database of systematic reviews · 2018
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Albert TucaCancer and Hematological Diseases Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
Ernest Guell
Emilio Martinez-Losada
Nuria Codorniu
Institut Català d'Oncologia · ESHospital Clínic de Barcelona · ESHospital de Sant Pau · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant bowel obstruction (MBO) is a frequent complication in advanced cancer patients, especially in those with abdominal tumors. Clinical management of MBO requires a specific and individualized approach that is based on disease prognosis and the objectives of care. The global prevalence of MBO is estimated to be 3% to 15% of cancer patients. Surgery should always be considered for patients in the initial stages of the disease with a preserved general status and a single level of occlusion. Less invasive approaches such as duodenal or colonic stenting should be considered when surgery is contraindicated in obstructions at the single level. The priority of care for inoperable and consolidated MBO is to control symptoms and promote the maximum level of comfort possible. The spontaneous resolution of an inoperable obstructive process is observed in more than one third of patients. The mean survival is of no longer than 4-5 weeks in patients with consolidated MBO. Polymodal medical treatment based on a combination of glucocorticoids, strong opioids, antiemetics, and antisecretory drugs achieves very high symptomatic control. This review focuses on the epidemiological aspects, diagnosis, surgical criteria, medical management, and factors influencing the spontaneous resolution of MBO in advanced cancer patients.

Indexed as

bowel occlusioncancerintestinal obstructionmalignant bowel obstruction

Identifiers

PMID22904637
PMCPMC3421464
OpenAlexW2026088639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.